Fap/cd40 binding molecule and medicinal use thereof
AssigneesJiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd.
InventorsYuan Lin, Simeng Chen, Tingting Wu, Rongting Hu, Cheng Liao
Life of this patent
Estimating the term…
Abstract
An FAP/CD40 binding molecule and the medicinal use thereof. Specifically, provided are an FAP binding molecule, a CD40 binding molecule and an FAP/CD40 binding molecule, a method for preventing and treating diseases (such as tumors or cancers) using same, and the medicinal use thereof.
Claims29
A FAP/CD40-binding molecule, comprising a first antigen-binding domain that specifically binds to FAP and a second antigen-binding domain that specifically binds to CD40, wherein the first antigen-binding domain that specifically binds to FAP comprises a heavy chain variable region and a light chain variable region;
- the heavy chain variable region comprises a HCDR1, a HCDR2 and a HCDR3, and the light chain variable region comprises a LCDR1, a LCDR2 and a LCDR3, wherein:
- the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 9, 10 and 18, respectively;
- the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 12, 13 and 19, respectively;
- the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 9, 10 and 15, respectively;
- the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 12, 13 and 14, respectively;
- the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 9, 10 and 11, respectively;
- the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 12, 13 and 14, respectively;
- the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 9, 10 and 15, respectively;
- the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 12, 13 and 16, respectively;
- or
- the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 9, 10 and 11, respectively;
- the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 12, 13 and 17, respectively.
A FAP-binding molecule, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, a HCDR2 and a HCDR3, and the light chain variable region comprises a LCDR1, a LCDR2 and a LCDR3, wherein:
- the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 9, 10 and 18, respectively;
- the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 12, 13 and 19, respectively;
- the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 9, 10 and 15, respectively;
- the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 12, 13 and 14, respectively;
- the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 9, 10 and 11, respectively;
- the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 12, 13 and 14, respectively;
- the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 9, 10 and 15, respectively;
- the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 12, 13 and 16, respectively;
- or
- the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 9, 10 and 11, respectively;
- the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 12, 13 and 17, respectively.
A CD40-binding molecule, comprising an immunoglobulin single variable domain that binds to CD40, wherein the immunoglobulin single variable domain comprises three complementarity-determining regions CDR1, CDR2 and CDR3, wherein:
- the CDR1, CDR2 and CDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 39, 40 and 41, respectively;
- the CDR1, CDR2 and CDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 24, 25 and 26, respectively;
- or
- the CDR1, CDR2 and CDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 27, 28 and 29, respectively.
A FAP/CD40-binding molecule comprising a first antigen-binding domain that specifically binds to FAP and a second antigen-binding domain that specifically binds to CD40, wherein the second antigen-binding domain that specifically binds to CD40 comprises at least one immunoglobulin single variable domain, and the immunoglobulin single variable domain comprises three complementarity-determining regions CDR, CDR2 and CDR3, wherein:
- the CDR1, CDR2 and CDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 39, 40 and 41, respectively;
- the CDR1, CDR2 and CDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 24, 25 and 26, respectively;
- or
- the CDR1, CDR2 and CDR3 comprise the amino acid sequences set forth in SEQ ID NOs:
- 27, 28 and 29, respectively.
(canceled)
Dependencies are inferred from the claim text.